<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p189" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_189{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_189{left:306px;bottom:30px;}
#t3_189{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_189{left:346px;bottom:30px;}
#t5_189{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_189{left:517px;bottom:30px;}
#t7_189{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_189{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_189{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_189{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_189{left:35px;bottom:777px;letter-spacing:0.05px;word-spacing:0.13px;}
#tc_189{left:35px;bottom:754px;letter-spacing:0.09px;word-spacing:0.1px;}
#td_189{left:35px;bottom:731px;letter-spacing:0.15px;word-spacing:0.04px;}
#te_189{left:35px;bottom:707px;letter-spacing:0.05px;word-spacing:-1.1px;}
#tf_189{left:35px;bottom:684px;letter-spacing:-0.12px;}
#tg_189{left:100px;bottom:692px;letter-spacing:-0.01px;}
#th_189{left:123px;bottom:684px;letter-spacing:0.11px;word-spacing:0.08px;}
#ti_189{left:35px;bottom:661px;letter-spacing:0.08px;word-spacing:-0.97px;}
#tj_189{left:35px;bottom:638px;letter-spacing:0.11px;word-spacing:0.08px;}
#tk_189{left:35px;bottom:599px;letter-spacing:0.14px;word-spacing:0.05px;}
#tl_189{left:35px;bottom:575px;letter-spacing:0.11px;word-spacing:0.08px;}
#tm_189{left:35px;bottom:552px;letter-spacing:0.1px;word-spacing:0.08px;}
#tn_189{left:35px;bottom:529px;letter-spacing:0.13px;word-spacing:0.05px;}
#to_189{left:35px;bottom:506px;letter-spacing:0.15px;word-spacing:-0.66px;}
#tp_189{left:35px;bottom:482px;letter-spacing:0.06px;word-spacing:-0.12px;}
#tq_189{left:35px;bottom:459px;letter-spacing:0.14px;word-spacing:-0.57px;}
#tr_189{left:312px;bottom:467px;}
#ts_189{left:357px;bottom:459px;letter-spacing:0.15px;word-spacing:0.04px;}
#tt_189{left:35px;bottom:436px;letter-spacing:0.14px;word-spacing:0.05px;}
#tu_189{left:35px;bottom:413px;letter-spacing:0.19px;}
#tv_189{left:367px;bottom:420px;letter-spacing:0.12px;}
#tw_189{left:35px;bottom:372px;letter-spacing:0.12px;word-spacing:-1.16px;}
#tx_189{left:35px;bottom:349px;letter-spacing:0.07px;word-spacing:0.12px;}
#ty_189{left:35px;bottom:326px;letter-spacing:0.17px;word-spacing:0.02px;}
#tz_189{left:35px;bottom:303px;letter-spacing:0.13px;word-spacing:0.06px;}
#t10_189{left:35px;bottom:280px;letter-spacing:0.03px;word-spacing:-0.9px;}
#t11_189{left:35px;bottom:256px;letter-spacing:0.09px;word-spacing:0.1px;}
#t12_189{left:35px;bottom:233px;letter-spacing:0.16px;word-spacing:0.03px;}
#t13_189{left:361px;bottom:241px;letter-spacing:-0.01px;}
#t14_189{left:384px;bottom:233px;letter-spacing:0.14px;word-spacing:0.04px;}
#t15_189{left:35px;bottom:210px;letter-spacing:0.08px;word-spacing:0.1px;}
#t16_189{left:35px;bottom:187px;letter-spacing:0.13px;word-spacing:0.07px;}
#t17_189{left:35px;bottom:163px;letter-spacing:0.18px;}
#t18_189{left:35px;bottom:140px;letter-spacing:0.13px;word-spacing:0.06px;}
#t19_189{left:35px;bottom:101px;letter-spacing:0.04px;word-spacing:0.14px;}
#t1a_189{left:35px;bottom:78px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t1b_189{left:391px;bottom:85px;letter-spacing:0.12px;}
#t1c_189{left:458px;bottom:78px;letter-spacing:-0.31px;}
#t1d_189{left:35px;bottom:55px;letter-spacing:0.13px;word-spacing:0.05px;}
#t1e_189{left:618px;bottom:777px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1f_189{left:618px;bottom:754px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1g_189{left:618px;bottom:731px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1h_189{left:818px;bottom:738px;letter-spacing:0.1px;}
#t1i_189{left:863px;bottom:731px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1j_189{left:618px;bottom:707px;letter-spacing:0.16px;word-spacing:-0.22px;}
#t1k_189{left:618px;bottom:684px;letter-spacing:0.11px;word-spacing:0.07px;}
#t1l_189{left:618px;bottom:645px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1m_189{left:618px;bottom:616px;letter-spacing:0.11px;word-spacing:0.09px;}
#t1n_189{left:618px;bottom:592px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1o_189{left:618px;bottom:569px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1p_189{left:1055px;bottom:569px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1q_189{left:618px;bottom:546px;letter-spacing:0.44px;}
#t1r_189{left:683px;bottom:546px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1s_189{left:1095px;bottom:554px;}
#t1t_189{left:1140px;bottom:546px;letter-spacing:0.45px;}
#t1u_189{left:618px;bottom:523px;letter-spacing:0.1px;word-spacing:-1.02px;}
#t1v_189{left:618px;bottom:500px;letter-spacing:0.11px;word-spacing:-0.06px;}
#t1w_189{left:618px;bottom:476px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1x_189{left:618px;bottom:453px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1y_189{left:618px;bottom:430px;letter-spacing:0.04px;word-spacing:0.14px;}
#t1z_189{left:771px;bottom:430px;letter-spacing:0.21px;word-spacing:-0.02px;}
#t20_189{left:952px;bottom:430px;letter-spacing:0.11px;word-spacing:0.07px;}
#t21_189{left:618px;bottom:407px;word-spacing:0.18px;}
#t22_189{left:618px;bottom:383px;letter-spacing:0.09px;word-spacing:0.09px;}
#t23_189{left:618px;bottom:343px;letter-spacing:0.09px;word-spacing:0.09px;}
#t24_189{left:618px;bottom:320px;letter-spacing:0.19px;}
#t25_189{left:1056px;bottom:320px;letter-spacing:0.1px;word-spacing:0.09px;}
#t26_189{left:618px;bottom:297px;letter-spacing:0.12px;word-spacing:-0.18px;}
#t27_189{left:618px;bottom:273px;letter-spacing:0.1px;word-spacing:0.08px;}
#t28_189{left:618px;bottom:250px;letter-spacing:0.05px;word-spacing:0.14px;}
#t29_189{left:618px;bottom:227px;letter-spacing:0.12px;}
#t2a_189{left:694px;bottom:235px;letter-spacing:0.08px;}
#t2b_189{left:783px;bottom:227px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2c_189{left:618px;bottom:204px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2d_189{left:618px;bottom:181px;letter-spacing:0.17px;word-spacing:0.01px;}
#t2e_189{left:618px;bottom:159px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2f_189{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_189{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_189{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_189{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_189{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_189{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_189{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_189{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_189{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts189" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg189Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg189" style="-webkit-user-select: none;"><object width="1210" height="935" data="189/189.svg" type="image/svg+xml" id="pdf189" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_189" class="t s0_189">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_189" class="t s1_189">© </span>
<span id="t3_189" class="t s0_189">(NCCN </span>
<span id="t4_189" class="t s1_189">© </span>
<span id="t5_189" class="t s0_189">), All rights reserved. NCCN Guidelines </span>
<span id="t6_189" class="t s1_189">® </span>
<span id="t7_189" class="t s0_189">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_189" class="t s2_189">NCCN Guidelines Version 4.2024 </span>
<span id="t9_189" class="t s2_189">Head and Neck Cancers </span>
<span id="ta_189" class="t s3_189">MS-48 </span>
<span id="tb_189" class="t s4_189">including 123 patients with stage III or IV sinonasal squamous cell </span>
<span id="tc_189" class="t s4_189">carcinoma treated from 1988 to 2017 at an NCCN Member Institution </span>
<span id="td_189" class="t s4_189">showed an ORR of 62.6% (71 partial responses, 6 complete responses) </span>
<span id="te_189" class="t s4_189">following treatment with induction chemotherapy using regimens typical for </span>
<span id="tf_189" class="t s4_189">SCCHN. </span>
<span id="tg_189" class="t s5_189">595 </span>
<span id="th_189" class="t s4_189">Two-year OS, 2-year DFS, and rate of orbital preservation </span>
<span id="ti_189" class="t s4_189">were 61.4%, 67.9%, and 81.5%, respectively. Distant metastasis occurred </span>
<span id="tj_189" class="t s4_189">in only 6.5%. </span>
<span id="tk_189" class="t s4_189">Systemic therapy should routinely be part of the overall treatment for </span>
<span id="tl_189" class="t s4_189">patients with SNUC with neuroendocrine features; small cell, high-grade </span>
<span id="tm_189" class="t s4_189">olfactory esthesioneuroblastoma; midline NUT; or SNEC histologies The </span>
<span id="tn_189" class="t s4_189">optimal regimen for these patients is not well-defined, but typically </span>
<span id="to_189" class="t s4_189">regimens used for high-grade neuroendocrine carcinomas (eg, etoposide </span>
<span id="tp_189" class="t s4_189">plus platinum, cyclophosphamide/doxorubicin/vincristine) or for advanced </span>
<span id="tq_189" class="t s4_189">SCCHN (eg, TPF, PF, TP) are used. </span>
<span id="tr_189" class="t s5_189">596-605 </span>
<span id="ts_189" class="t s4_189">After curative-intent treatment, </span>
<span id="tt_189" class="t s4_189">long-term follow-up is necessary for esthesioneuroblastoma, since late </span>
<span id="tu_189" class="t s4_189">recurrences can occur even after 15 years. </span>
<span id="tv_189" class="t s5_189">604,606,607 </span>
<span id="tw_189" class="t s4_189">Induction chemotherapy is an option for patients with newly diagnosed T3, </span>
<span id="tx_189" class="t s4_189">T4a disease, and options are based on molecular features. In a single </span>
<span id="ty_189" class="t s4_189">center retrospective study including 95 patients with SNUC, concurrent </span>
<span id="tz_189" class="t s4_189">systemic therapy/RT following complete or partial response to induction </span>
<span id="t10_189" class="t s4_189">chemotherapy (ie, etoposide with platinum-based therapy) was associated </span>
<span id="t11_189" class="t s4_189">with a 5-year DSS rate of 81% (95% CI, 69%–88%), compared to 59% </span>
<span id="t12_189" class="t s4_189">(95% CI, 53%–66%) for the entire sample. </span>
<span id="t13_189" class="t s5_189">608 </span>
<span id="t14_189" class="t s4_189">The DSS rate for patients </span>
<span id="t15_189" class="t s4_189">who received surgery with adjuvant therapy following a less than partial </span>
<span id="t16_189" class="t s4_189">response to induction chemotherapy was 39% (95% CI, 30%–46%). </span>
<span id="t17_189" class="t s4_189">Definitive trials of induction chemotherapy prior to surgery are currently </span>
<span id="t18_189" class="t s4_189">underway within the U.S. cooperative groups. </span>
<span id="t19_189" class="t s4_189">For patients with metastatic disease, options include platinum combined </span>
<span id="t1a_189" class="t s4_189">with etoposide (with or without concurrent RT) </span>
<span id="t1b_189" class="t s5_189">596,609,610 </span>
<span id="t1c_189" class="t s4_189">and </span>
<span id="t1d_189" class="t s4_189">cyclophosphamide/doxorubicin/vincristine (category 2B). While there </span>
<span id="t1e_189" class="t s4_189">remains no known effective treatment for metastatic midline NUT </span>
<span id="t1f_189" class="t s4_189">carcinoma, there are targeted therapies such as bromodomain inhibitors </span>
<span id="t1g_189" class="t s4_189">under active investigation. </span>
<span id="t1h_189" class="t s5_189">611,612 </span>
<span id="t1i_189" class="t s4_189">Because of a paucity of data concerning </span>
<span id="t1j_189" class="t s4_189">the use of systemic therapies, appropriate use of other systemic options, </span>
<span id="t1k_189" class="t s4_189">including immunotherapy, remains undefined. </span>
<span id="t1l_189" class="t s3_189">Maxillary Sinus Tumors </span>
<span id="t1m_189" class="t s4_189">Surgical resection followed by postoperative radiotherapy remains a </span>
<span id="t1n_189" class="t s4_189">cornerstone of treatment for most maxillary sinus tumors, except limited </span>
<span id="t1o_189" class="t s4_189">extent T1–2 tumors resected with negative margins (see </span><span id="t1p_189" class="t s6_189">Maxillary Sinus </span>
<span id="t1q_189" class="t s6_189">Tumors </span><span id="t1r_189" class="t s4_189">in the NCCN Guidelines for Head and Neck Cancers). </span>
<span id="t1s_189" class="t s5_189">613-616 </span>
<span id="t1t_189" class="t s4_189">The </span>
<span id="t1u_189" class="t s4_189">principles are generally similar to those described above for ethmoid sinus </span>
<span id="t1v_189" class="t s4_189">tumors. For patients with SNUC with neuroendocrine features; small cell, </span>
<span id="t1w_189" class="t s4_189">high-grade olfactory esthesioneuroblastoma; or midline NUT or SNEC </span>
<span id="t1x_189" class="t s4_189">histologies, systemic therapy should be routinely included as part of the </span>
<span id="t1y_189" class="t s4_189">treatment plan (see </span><span id="t1z_189" class="t s6_189">Ethmoid Sinus Tumors </span><span id="t20_189" class="t s4_189">in this Discussion). </span>
<span id="t21_189" class="t s4_189">Participation in clinical trials is recommended for patients with malignant </span>
<span id="t22_189" class="t s4_189">tumors of the paranasal sinuses with these histologies. </span>
<span id="t23_189" class="t s4_189">RT fractionation for patients with maxillary sinus tumors is described in </span>
<span id="t24_189" class="t s6_189">Maxillary Sinus Tumors: Principles of Radiation Therapy </span><span id="t25_189" class="t s4_189">in the NCCN </span>
<span id="t26_189" class="t s4_189">Guidelines for Head and Neck Cancers. Studies using IMRT have shown </span>
<span id="t27_189" class="t s4_189">that it reduces the incidence of complications, such as radiation-induced </span>
<span id="t28_189" class="t s4_189">ophthalmic toxicity, although the 5-year OS rate was not </span>
<span id="t29_189" class="t s4_189">improved. </span>
<span id="t2a_189" class="t s5_189">220,615,617-620 </span>
<span id="t2b_189" class="t s4_189">Similar to the recommendation for ethmoid sinus </span>
<span id="t2c_189" class="t s4_189">tumors, IMRT is preferred in this anatomic area due to proximity to the </span>
<span id="t2d_189" class="t s4_189">visual structures and proton therapy is preferred if the normal tissue </span>
<span id="t2e_189" class="t s4_189">constraints cannot be met by IMRT. </span>
<span id="t2f_189" class="t s7_189">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
